Patent 11589880
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 11589880. The free-form analysis below may also discuss cases beyond this list.
- Angiodynamics Inc v. Endovascular Engineering Incfiled Apr 23, 20261:26-cv-00469Delaware District CourtOpen
Defendants: Endovascular Engineering Inc
Other patents asserted: 8613717, 12496077
The lawsuit targets the Viper and Cobra catheters and their associated medical system for removing blood clots. This system includes a pump, a blood/clot collection device, and other related components.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Litigation Status of U.S. Patent No. 11,589,880
As of April 26, 2026, U.S. Patent No. 11,589,880 is involved in one known litigation case. Details of the case are provided below.
Case 1: AngioDynamics, Inc. v. Endovascular Engineering, Inc.
- Plaintiff(s): AngioDynamics, Inc.
- Defendant(s): Endovascular Engineering, Inc. (also referred to as "E2")
- Jurisdiction: U.S. District Court for the District of Delaware
- Case Number: Specific case number not available in the public reports.
- Filing Date: April 23, 2026
- Status: Open / Recently filed.
- Details:
- The complaint filed by AngioDynamics, Inc. alleges that Endovascular Engineering's Hēlo Thrombectomy System infringes upon several of its patents.
- Specifically, U.S. Patent No. 11,589,880 is asserted, along with U.S. Patent Nos. 8,613,717 and 12,496,077.
- The technology in question relates to a proprietary self-expanding funnel design used in catheter-based systems to remove blood clots (thrombi and emboli) from blood vessels. This is consistent with the claims of the '880 patent, which cover methods of capturing dislodged material using a cannula with a funnel-shaped tip.
- AngioDynamics is seeking remedies that include damages (lost profits and a reasonable royalty) and both preliminary and permanent injunctions to stop the alleged unauthorized use of its patented technology.
- The lawsuit asserts that AngioDynamics' own products, the AngioVac and AlphaVac systems, utilize the patented technology.
Generated 5/10/2026, 1:53:15 AM